High l-carnitine concentrations do not prevent late diabetic complications in type 1 and 2 diabetic patients

Nutrition Research

Volumn 32, Issue 5, 2012, Pages 320-327

  Liepinsh, Edgars ^a   Skapare, Elina ^a,b   Vavers, Edijs ^a,b   Konrade, Ilze ^a,b   Strele, Ieva ^b   Grinberga, Solveiga ^a   Pugovics, Osvalds ^a   Dambrova, Maija ^a,b  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

L Carnitine; Late complications; Nephropathy; Neuropathy; Patients with type 1 and type 2 diabetes mellitus; Retinopathy

Indexed keywords

C PEPTIDE; CARNITINE; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; CARNITINE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE;

EID: 84861716714     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.03.010     Document Type: Article

References (45)

1. Golbidi S., Ebadi S.A., Laher I. Antioxidants in the treatment of diabetes. Curr Diabetes Rev 2011, 7:106-125.
2. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983, 63:1420-1480.
3. Mynatt R.L. Carnitine and type 2 diabetes. Diabetes Metab Res Rev 2009, 25:45-49.
4. Poorabbas A., Fallah F., Bagdadchi J., Mahdavi R., Aliasgarzadeh A., Asadi Y., et al. Determination of free l-carnitine levels in type II diabetic women with and without complications. Eur J Clin Nutr 2007, 61:892-895.
5. Power R.A., Hulver M.W., Zhang J.Y., Dubois J., Marchand R.M., Ilkayeva O., et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007, 50:824-832.
6. Ramsay R.R., Gandour R.D., van der Leij F.R. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 2001, 1546:21-43.
7. Bieber L.L. Carnitine. Annu Rev Biochem 1988, 57:261-283.
8. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann N Y Acad Sci 2004, 1033:30-41.
9. Pregant P., Schernthaner G., Legenstein E., Lienhart L., Bruck S., Schnack C., et al. Decreased plasma carnitine in type I diabetes mellitus. Klin Wochenschr 1991, 69:511-516.
10. Soltesz G., Melegh B., Sandor A. The relationship between carnitine and ketone body levels in diabetic children. Acta Paediatr Scand 1983, 72:511-515.
11. Winter S.C., Simon M., Zorn E.M., Szabo-Aczel S., Vance W.H., O'Hara T., et al. Relative carnitine insufficiency in children with type I diabetes mellitus. Am J Dis Child 1989, 143:1337-1339.
12. Tamamogullari N., Silig Y., Icagasioglu S., Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications 1999, 13:251-253.
13. Okuda Y., Kawai K., Murayama Y., Yamashita K. Postprandial changes in plasma ketone body and carnitine levels in normal and non-insulin-dependent diabetic subjects. Endocrinol Jpn 1987, 34:415-422.
14. Pregant P., Kaiser E., Schernthaner G. No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients. Clin Investig 1993, 71:610-612.
15. Jacobson J.D., Midyett L.K., Garg U., Sherman A.K., Patel C. Biochemical evidence for reduced carnitine palmitoyltransferase 1 (CPT-1) activity in type 1 diabetes mellitus. J Diabetes Metab 2011, 2:144.
16. Capaldo B., Napoli R., Di B.P., Albano G., Sacca L. Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991, 14:191-195.
17. Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci 2004, 1033:99-107.
18. Malone J.I., Schocken D.D., Morrison A.D., Gilbert-Barness E. Diabetic cardiomyopathy and carnitine deficiency. J Diabetes Complications 1999, 13:86-90.
19. Malone J.I., Cuthbertson D.D., Malone M.A., Schocken D.D. Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats. Cardiovasc Diabetol 2006, 5:2.
20. Sena C.M., Nunes E., Louro T., Proenca T., Fernandes R., Boarder M.R., et al. Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats. Br J Pharmacol 2008, 153:894-906.
21. Gonzalez-Ortiz M., Hernandez-Gonzalez S.O., Hernandez-Salazar E., Martinez-Abundis E. Effect of oral l-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients. Ann Nutr Metab 2008, 52:335-338.
22. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2007, 30:42-47.
23. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
24. Liepinsh E., Konrade I., Skapare E., Pugovics O., Grinberga S., Kuka J., et al. Mildronate treatment alters gamma-butyrobetaine and l-carnitine concentrations in healthy volunteers. J Pharm Pharmacol 2011, 63:1195-1201.
25. Young M.J., Boulton A.J., MacLeod A.F., Williams D.R., Sonksen P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36:150-154.
26. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
27. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS Report Number 10. Ophthalmology 1991, 98:786-806. Early Treatment Diabetic Retinopathy Study Research Group.
28. Whitworth J.A. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21:1983-1992.
29. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
30. Flanagan J.L., Simmons P.A., Vehige J., Willcox M.D., Garrett Q. Role of carnitine in disease. Nutr Metab (Lond) 2010, 7:30.
31. Longo N., Amat di San Filippo C., Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006, 142:77-85.
32. Demarquoy J., Georges B., Rigault C., Royer M., Clairet A., Soty M., et al. Radioisotopic determination of l-carnitine content in foods commonly eaten in Western countries. Food Chemistry 2004, 86:137-142.
33. American Diabetes Association Standards of medical care in diabetes-2011. Diabetes Care 2011, 34:11-61.
34. Hodge A.M., English D.R., Itsiopoulos C., O'Dea K., Giles G.G. Does a Mediterranean diet reduce the mortality risk associated with diabetes: evidence from the Melbourne Collaborative Cohort Study. Nutr Metab Cardiovasc Dis 2010, 21:733-739.
35. Aune D., Ursin G., Veierod M.B. Meat consumption and the risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia 2009, 52:2277-2287.
36. Craig W.J. Nutrition concerns and health effects of vegetarian diets. Nutr Clin Pract 2010, 25:613-620.
37. Psaltopoulou T., Ilias I., Alevizaki M. The role of diet and lifestyle in primary, secondary, and tertiary diabetes prevention: a review of meta-analyses. Rev Diabet Stud 2010, 7:26-35.
38. Vernez L., Dickenmann M., Steiger J., Wenk M., Krahenbuhl S. Effect of l-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol Dial Transplant 2006, 21:450-458.
39. Verrina E., Caruso U., Calevo M.G., Emma F., Sorino P., De P.T., et al. Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr Nephrol 2007, 22:727-733.
40. Hurot J.M., Cucherat M., Haugh M., Fouque D. Effects of l-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002, 13:708-714.
41. Delanghe J., De Slypere J.P., De B.M., Robbrecht J., Wieme R., Vermeulen A. Normal reference values for creatine, creatinine, and carnitine are lower in vegetarians. Clin Chem 1989, 35:1802-1803.
42. Barnard N.D., Gloede L., Cohen J., Jenkins D.J., Turner-McGrievy G., Green A.A., et al. A low-fat vegan diet elicits greater macronutrient changes, but is comparable in adherence and acceptability, compared with a more conventional diabetes diet among individuals with type 2 diabetes. J Am Diet Assoc 2009, 109:263-272.
43. Kahleova H., Matoulek M., Malinska H., Oliyarnik O., Kazdova L., Neskudla T., et al. Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with type 2 diabetes. Diabet Med 2011, 28:549-559.
44. Bain M.A., Milne R.W., Evans A.M. Disposition and metabolite kinetics of oral l-carnitine in humans. J Clin Pharmacol 2006, 46:1163-1170.
45. Ramos-Roman M.A., Sweetman L., Valdez M.J., Parks E.J. Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. Metabolism 2012, 61:202-212.